[go: up one dir, main page]

ATE302771T1 - Indolinon-derivative als protein-kinasehemmer - Google Patents

Indolinon-derivative als protein-kinasehemmer

Info

Publication number
ATE302771T1
ATE302771T1 AT02796035T AT02796035T ATE302771T1 AT E302771 T1 ATE302771 T1 AT E302771T1 AT 02796035 T AT02796035 T AT 02796035T AT 02796035 T AT02796035 T AT 02796035T AT E302771 T1 ATE302771 T1 AT E302771T1
Authority
AT
Austria
Prior art keywords
sup
kinase inhibitors
protein kinase
indolinone derivatives
indolinone
Prior art date
Application number
AT02796035T
Other languages
English (en)
Inventor
John H Griffin
Roger Briesewitz
Jonathan W Wray
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE302771T1 publication Critical patent/ATE302771T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT02796035T 2001-12-27 2002-12-20 Indolinon-derivative als protein-kinasehemmer ATE302771T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34381301P 2001-12-27 2001-12-27
US34374601P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE302771T1 true ATE302771T1 (de) 2005-09-15

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796035T ATE302771T1 (de) 2001-12-27 2002-12-20 Indolinon-derivative als protein-kinasehemmer

Country Status (21)

Country Link
US (3) US6686362B2 (de)
EP (1) EP1458713B1 (de)
JP (1) JP4363985B2 (de)
KR (1) KR100965519B1 (de)
CN (1) CN1290844C (de)
AT (1) ATE302771T1 (de)
AU (1) AU2002360753B2 (de)
BR (1) BR0215360A (de)
CA (1) CA2470480C (de)
CO (1) CO5611126A2 (de)
DE (1) DE60205776T2 (de)
DK (1) DK1458713T3 (de)
ES (1) ES2247411T3 (de)
HU (1) HUP0500111A3 (de)
IL (1) IL162203A0 (de)
MX (1) MXPA04006271A (de)
NO (1) NO327550B1 (de)
NZ (1) NZ533219A (de)
PL (1) PL208283B1 (de)
RU (1) RU2316554C2 (de)
WO (1) WO2003057690A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015082A2 (en) * 2002-08-09 2004-02-19 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
BRPI0415773A (pt) * 2003-10-24 2006-12-26 Schering Ag derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer
EP1699477A2 (de) * 2003-12-11 2006-09-13 Theravance, Inc. Zusammensetzungen zur verwendung bei der behandlung von durch mutierte rezeptor-tyrosinkinase angetriebene zellproliferationserkrankungen
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
WO2007048088A2 (en) 2005-10-18 2007-04-26 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
BRPI0710548B8 (pt) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP5089681B2 (ja) 2006-04-20 2012-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ c−fmsキナーゼの阻害剤としての複素環式化合物
JP2010502741A (ja) * 2006-09-11 2010-01-28 キュリス,インコーポレイテッド Ptkインヒビターとしての亜鉛結合部分を含む置換2−インドリノン
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
SG182480A1 (en) 2010-01-12 2012-08-30 Ab Science Thiazole and oxazole kinase inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
ES2608628T3 (es) 2012-08-07 2017-04-12 Janssen Pharmaceutica Nv Procedimiento para la preparacion de derivados de ester heterociclicos
TWI569799B (zh) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 抑制組成型活性磷酸化flt3激酶的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
BR112017002001B1 (pt) 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
EP3254698A1 (de) 2016-06-08 2017-12-13 Universite De Montpellier Flt3-rezeptor-inhibitoren bei niedriger dosierung zur behandlung von neuropathischem schmerz
JP2019532011A (ja) 2016-11-02 2019-11-07 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. Flt3突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
CN111093640A (zh) 2017-05-17 2020-05-01 国家健康与医学研究院 用于改善阿片类药物疼痛治疗的flt3抑制剂
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP4528440B2 (ja) 1998-05-29 2010-08-18 スージェン, インク. ピロール置換2−インドリノンタンパク質キナーゼ阻害剤
DK1157019T3 (da) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl- (og alkynyl-)oxindoler som inhibitorer af cyklinafhængige kinaser, især CDK2
AU760964B2 (en) 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU6998000A (en) 1999-08-27 2001-03-26 Boehringer Ingelheim Pharma Kg Substituted indolinones as tyrosine kinase inhibitors
ES2225231T3 (es) 1999-10-06 2005-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas.
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2576501A (en) 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
DE122008000002I1 (de) * 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
AU2001270260A1 (en) 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
JP5073147B2 (ja) 2000-08-18 2012-11-14 ミレニアム ファーマシューティカルズ インク. キナーゼインヒビターとしてのキナゾリン誘導体
US6677368B2 (en) 2000-12-20 2004-01-13 Sugen, Inc. 4-aryl substituted indolinones
WO2004015082A2 (en) * 2002-08-09 2004-02-19 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
EP1699477A2 (de) 2003-12-11 2006-09-13 Theravance, Inc. Zusammensetzungen zur verwendung bei der behandlung von durch mutierte rezeptor-tyrosinkinase angetriebene zellproliferationserkrankungen

Also Published As

Publication number Publication date
DE60205776T2 (de) 2006-06-14
DK1458713T3 (da) 2005-10-31
MXPA04006271A (es) 2004-10-04
CA2470480C (en) 2010-12-14
DE60205776D1 (en) 2005-09-29
JP2005514420A (ja) 2005-05-19
PL369602A1 (en) 2005-05-02
EP1458713B1 (de) 2005-08-24
HUP0500111A3 (en) 2009-10-28
CO5611126A2 (es) 2006-02-28
EP1458713A1 (de) 2004-09-22
US7060703B2 (en) 2006-06-13
CN1290844C (zh) 2006-12-20
BR0215360A (pt) 2004-12-14
WO2003057690A1 (en) 2003-07-17
NO20042926L (no) 2004-07-08
RU2004122918A (ru) 2005-03-27
US20060142281A1 (en) 2006-06-29
AU2002360753A1 (en) 2003-07-24
ES2247411T3 (es) 2006-03-01
AU2002360753B2 (en) 2008-08-21
CN1608063A (zh) 2005-04-20
IL162203A0 (en) 2005-11-20
US20030171378A1 (en) 2003-09-11
US6686362B2 (en) 2004-02-03
HK1068886A1 (en) 2005-05-06
RU2316554C2 (ru) 2008-02-10
JP4363985B2 (ja) 2009-11-11
CA2470480A1 (en) 2003-07-17
NO327550B1 (no) 2009-08-10
KR20040070283A (ko) 2004-08-06
HUP0500111A2 (hu) 2005-07-28
US20040198804A1 (en) 2004-10-07
KR100965519B1 (ko) 2010-06-23
US7223783B2 (en) 2007-05-29
PL208283B1 (pl) 2011-04-29
NZ533219A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
ATE302771T1 (de) Indolinon-derivative als protein-kinasehemmer
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DK1242382T3 (da) Tricycliske proteinkinaseinhibitorer
CY1106165T1 (el) Παραγωγα ινδολινονης για την τροποποιηση της c-kit πρωτεϊνικης τυροσινικης κινασης
NO2008019I2 (no) Sunitinib
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
DE69434955D1 (de) Aryliden und Heteroaryliden-oxindolderivate als Tyrosin Kinase Inhibitoren
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
TNSN03055A1 (en) 3-(4-amidopyrrol -2-ylmethlidene)-2- indolinone derivatives as protein kinase inhibitors
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
ATE554087T1 (de) Neue kinaseinhibitoren
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
DE60206762D1 (de) Hexahydroazepino[4,5-g]indole und -indoline als 5-ht-rezeptor-liganden
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren
AU2002366563A1 (en) Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1458713

Country of ref document: EP